-

CivaTech Oncology selected to present at BIO International Conference

SAN DIEGO--(BUSINESS WIRE)--CivaTech Oncology Inc., a leading developer of radioactive cancer therapeutics made a presentation regarding the CivaSheet® at the annual Biotechnology Innovation Organization (BIO) Conference June 14, 2022 in San Diego California. BIO International connects top research and early stage innovations with industry and investors.

CivaTech Oncology's CivaSheet® was supported in development and in clinical trials by National Institutes of Health/National Cancer Institute and the Small Business Innovation Research (SBIR). SBIR, a government program coordinated by the Small Business Administration, plays a valuable role in the start up of new companies developing meaningful products to change lives and improve cancer outcomes. SBIR grants have continued to support small businesses seeking commercialization even in the midst of a global pandemic. Funds from the NCI SBIR have helped CivaSheet® technology gain ground despite the challenging healthcare environment.

Suzanne Babcock, CEO of CivaTech Oncology, indicated that “the role of the SBIR has been pivotal in developing the device and generating a platform that addresses many cancer types including non-small cell lung cancer, pancreatic, colorectal, head and neck, soft tissue sarcomas and more.”

CivaSheet®, a novel bio-absorbable, internal radiation treatment, is implanted in less than 30 minutes in the operating room at the time of surgery. It prevents cancer recurrence by delivering a highly targeted dose of radiation directly to the surgical margin where residual cancer cells may remain. Results from clinical trials have shown remarkable improvements in therapeutic outcomes.

CivaSheet® is a flexible, implantable intra-operative radiation therapy device (brachytherapy) which emits unidirectional radiation using integrated gold shielding. This provides a homogenous radiation dose on one side while protecting healthy tissues. This feature is entirely unique to CivaSheet® allowing physicians to safely deliver aggressive radiation doses immediately adjacent to healthy, sensitive tissue. No complications or radiation related side effects have been reported in patients to date.

About CivaTech Oncology:

For more information about CivaSheet or CivaTech Oncology, please visit www.civatechoncology.com or call 919-314-1515 (Randy Harrison).

Taylor RJ, Todor D, Kaplan BJ, Stover W, Fields EC. “CivaSheet intraoperative radiation therapy for pancreatic cancer.” Brachytherapy. 2022 Mar-Apr;21(2):255-259. doi: 10.1016/j.brachy.2021.10.007

Contacts

Randy Harrison
919-314-1515

Industry:

CivaTech Oncology Inc.

Release Summary
CivaTech Oncology presents CivaSheet at Bio International Conference.
Release Versions
English

Contacts

Randy Harrison
919-314-1515

More News From CivaTech Oncology Inc.

Profound Improvement for Pancreatic Cancer Patients Using CivaSheet®, a New Radiation Device

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--CivaTech Oncology Inc., announces CivaSheet® significantly boosts outcomes for borderline resectable and locally advanced pancreatic cancer patients. CivaSheet, an implantable, targeted, shielded radiation device delivers an aggressive dose immediately to the pancreas region following surgical resection. Studies have been conducted in multi-institutional settings, garnering support from the NIH/NCI and SBIR programs. This is the first analysis of o...

Cancer Experts Report Initial Findings of CivaSheet® Soft Tissue Sarcoma Registry

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Physicians from four medical centers recently published data this month from an initial six patients implanted with CivaSheet® to treat retroperitoneal sarcoma. The article, titled “Initial Clinical Experience With Novel Directional Low-dose Rate Brachytherapy for Retroperitoneal Sarcoma” was accepted for publication in the Journal of Surgical Research on June 28, 2021. With a mean follow up of 16 months, no local cancer recurrences, no toxicities,...

CivaTech Oncology and NYU Langone Health Launch NIH-sponsored Trial to Fight Lung Cancer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Physicians from NYU Langone Health and its Perlmutter Cancer Center successfully treated their first patient in an NIH/NCI- sponsored clinical trial using CivaSheet® ,to improve lung cancer patients’ outcomes. The NYU Langone team, led by thoracic surgeon Michael Zervos, MD and radiation oncologist Benjamin Cooper, MD, affixed a custom sized CivaSheet® to the area of the patient’s lung needing treatment, following a robotic tumor resection. The pat...
Back to Newsroom